Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.62 |
| ▸ | NPC1 | O15118 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 5/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | CES1 | P23141 | 1/20 | 0.55 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.54 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.54 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11163745 | 0.88 | RAB9A (0.61) | RAB9ANPC1SMN1; SMN2TP53MAPT | |
| SCHEMBL31530471 | 0.87 | RAB9A (0.57) | RAB9ANPC1SMN1; SMN2TP53MAPT | |
| SCHEMBL5501691 | 0.86 | RAB9A (0.59) | RAB9ANPC1SMN1; SMN2TP53MAPT | |
| SCHEMBL6436191 | 0.85 | RAB9A (0.62) | RAB9ANPC1SMN1; SMN2TP53MAPT | |
| SCHEMBL8922768 | 0.85 | RAB9A (0.62) | RAB9ANPC1SMN1; SMN2TP53MAPT | |
| SCHEMBL27776364 | 0.84 | RAB9A (0.54) | RAB9ANPC1SMN1; SMN2TP53MAPT | |
| SCHEMBL26885172 | 0.84 | LMNA (0.61) | RAB9ANPC1SMN1; SMN2TP53MAPT | |
| SCHEMBL5940588 | 0.83 | RAB9A (0.68) | RAB9ANPC1SMN1; SMN2TP53MAPT | |
| SCHEMBL26885176 | 0.83 | SMN1; SMN2 (0.60) | RAB9ANPC1SMN1; SMN2TP53MAPT | |
| SCHEMBL4576386 | 0.83 | MEN1 (0.61) | RAB9ANPC1SMN1; SMN2TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104003939-A | Diaryl substituted glycolythiourea compounds as well as preparation method and application thereof | UNIV SHANDONG | 2014-08-27 | — | — | CN | claimed |
| EP-1332363-A4 | DETECTION OF NEURODEGENERATIVE DISORDERS | DOUBLE KAY (AU) | 2007-08-29 | — | — | EP | claimed |
| US-7005546-B2 | Acetamidobenzamide compounds for neurodegenerative disorders | RENOVIS, INC. (US) | 2006-02-28 | — | — | US | claimed |
| US-20050260577-A1 | Detection of neurodegenerative disorders | POWMRI LIMITED (AU) | 2005-11-24 | — | — | US | claimed |
| US-20040266881-A1 | Acetamidobenzamide compounds for neurodegenerative disorders | RENOVIS, INC. | 2004-12-30 | — | — | US | claimed |
| US-20040167226-A1 | Methods for the treatment of pain and traumatic injury using benzamides and compositions containing the same | RENOVIS, INC. | 2004-08-26 | — | — | US | claimed |
| EP-1332363-A1 | DETECTION OF NEURODEGENERATIVE DISORDERS | UNISEARCH LIMITED (AU) | 2003-08-06 | — | — | EP | claimed |
| WO-2002031499-A1 | DETECTION OF NEURODEGENERATIVE DISORDERS | UNISEARCH LIMITED (AU) | 2002-04-18 | — | — | WO | claimed |
| CN-1073552-C | Benzamides for neurodegenerative disorder treatment | CENTAUR PHARMACEUTICALS INC (US) | 2001-10-24 | — | — | CN | claimed |
| EP-0819113-B1 | BENZAMIDES FOR NEURODEGENERATIVE DISORDER TREATMENT | CENTAUR PHARMACEUTICALS INC (US) | 2001-06-27 | — | — | EP | claimed |
| US-6194465-B1 | ADMINISTERING ACETAMIDO-, NITRO-, OR AMINO-MONO- OR DISUBSTITUTED N-ALKYL BENZAMIDE COMPOUNDS SUCH AS N-TERT-BUTYL-4-ACETAMIDOBENZAMIDE FOR PROPHLAXIS OR TREATMENT OF AN INFLAMMATORY BOWEL CONDITION IN A PATIENT | CENTAUR PHARMACEUTICALS, INC. | 2001-02-27 | — | — | US | claimed |
| CN-1182416-A | Benzamides for neurodegenerative disorder treatment | CENTAUR PHARMACUETICALS INC (US) | 1998-05-20 | — | — | CN | claimed |
| EP-0819113-A1 | BENZAMIDES FOR NEURODEGENERATIVE DISORDER TREATMENT | CENTAUR PHARMACEUTICALS, INC. (US) | 1998-01-21 | — | — | EP | claimed |
| WO-1996031462-A1 | BENZAMIDES FOR NEURODEGENERATIVE DISORDER TREATMENT | CENTAUR PHARMACEUTICALS, INC. (US) | 1996-10-10 | — | — | WO | claimed |
| US-20230381159-A1 | SMALL MOLECULE INHIBITORS OF CORONAVIRUS ATTACHMENT AND ENTRY, METHODS AND USES THEREOF | UNIVERSITY OF MIAMI | 2023-11-30 | — | — | US | disclosed |
| US-20230365588-A1 | DIOL DESYMMETRIZATION BY NUCLEOPHILIC AROMATIC SUBSTITUTION | AMGEN INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-10011578-B2 | Compounds for stabilizing ryanodine receptors from aberrant levels of calcium release | ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE (US) | 2018-07-03 | — | — | US | disclosed |
| US-5643965-A | TREATMENT OF DOPAMINE ASSOCIATED NERVOUS SYSTEM DISORDERS | CENTAUR PHARMACEUTICALS, INC. (US) | 1997-07-01 | — | — | US | disclosed |
| US-5346691-A | FOR USE IN DERMATOLOGICAL AND COSMETIC COMPOSITIONS | 3V INC. (US) | 1994-09-13 | — | — | US | disclosed |
| EP-0570838-A1 | S-triazine derivatives as light stabilisers | 3V SIGMA S.p.A (IT) | 1993-11-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266881-A1 | Acetamidobenzamide compounds for neurodegenerative disorders | SNCA, PARK7, GBA1 | RAB9A 1226/4885NPC1 577/4885SMN1; SMN2 8/4885 |
| US-20230381159-A1 | SMALL MOLECULE INHIBITORS OF CORONAVIRUS ATTACHMENT AND ENTRY, METHODS AND USES THEREOF | ACE2, ACE, SARS1 | RAB9A 1817/4885NPC1 72/4885SMN1; SMN2 4878/4885 |
| US-20040167226-A1 | Methods for the treatment of pain and traumatic injury using benzamides and compositions containing the same | CNR1, NAA50, CNR2 | RAB9A 2735/4885NPC1 377/4885SMN1; SMN2 123/4885 |
| US-10011578-B2 | Compounds for stabilizing ryanodine receptors from aberrant levels of calcium release | CHERP, RYR1, RYR2 | RAB9A 586/4885NPC1 617/4885SMN1; SMN2 116/4885 |
| US-20230365588-A1 | DIOL DESYMMETRIZATION BY NUCLEOPHILIC AROMATIC SUBSTITUTION | MCL1, BAK1, BCL2A1 | RAB9A 1508/4885NPC1 1301/4885SMN1; SMN2 3223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.